UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

The dynamic effect of direct‐acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C

Journal of viral hepatitis, 2019-12, Vol.26 (12), p.1489-1492

2019

Volltextzugriff (PDF)

Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers

Pharmacoepidemiology and drug safety, 2023-04, Vol.32 (4), p.486-495

2023

Volltextzugriff (PDF)

Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort

Journal of viral hepatitis, 2023-03, Vol.30 (3), p.232-241

2023

Volltextzugriff (PDF)

Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort

Journal of viral hepatitis, 2020-10, Vol.27 (10), p.964-973

2020

Volltextzugriff (PDF)

Letter: tenofovir may be superior to entecavir for treatment‐naïve chronic hepatitis B patients—authors’ reply

Alimentary Pharmacology & Therapeutics (Suppl), 2021-05, Vol.53 (9), p.1050-1050

2021

Volltextzugriff (PDF)

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

Hepatology (Baltimore, Md.), 2022-07, Vol.76 (1), p.139-154

2022

Volltextzugriff (PDF)

Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination

BMC medical research methodology, 2017-12, Vol.17 (1), p.160-11, Article 160

2017

Volltextzugriff (PDF)

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic

JAMA internal medicine, 2022-01, Vol.182 (1), p.19

2022

Volltextzugriff (PDF)

Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population

Scientific reports, 2022-05, Vol.12 (1), p.8622-8622, Article 8622

2022

Volltextzugriff (PDF)

ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study

Scientific reports, 2023-03, Vol.13 (1), p.4775-4775, Article 4775

2023

Volltextzugriff (PDF)

Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model

Scientific reports, 2024-04, Vol.14 (1), p.9503-9503, Article 9503

2024

Volltextzugriff (PDF)

Publisher Correction: Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population

Scientific reports, 2022-06, Vol.12 (1), p.9405-9405, Article 9405

2022

Volltextzugriff (PDF)

Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution

JAMA network open, 2022-11, Vol.5 (11), p.e2240985-e2240985

2022

Volltextzugriff (PDF)

Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study

BMC infectious diseases, 2023-04, Vol.23 (1), p.228-228, Article 228

2023

Volltextzugriff (PDF)

Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France

Infection, 2022-02, Vol.50 (1), p.257-262

2022

Volltextzugriff (PDF)

Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies

The Journal of infectious diseases, 2024-05, Vol.229 (5), p.1341-1351

2024

Volltextzugriff (PDF)

Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies

The Journal of infectious diseases, 2023-11

2023

Volltextzugriff (PDF)

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

The Journal of infection, 2022-06, Vol.84 (6), p.e101-e104

2022

Volltextzugriff (PDF)

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir

Clinical microbiology and infection, 2023-04, Vol.29 (4), p.543.e5-543.e9

2023

Volltextzugriff (PDF)

Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response

Clinics and research in hepatology and gastroenterology, 2022-06, Vol.46 (6), p.101923-101923, Article 101923

2022

Volltextzugriff (PDF)

Corrigendum to: Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study

International journal of epidemiology, 2021-11, Vol.50 (5), p.1755-1755

2021

Volltextzugriff (PDF)

Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study

Clinics and research in hepatology and gastroenterology, 2021-09, Vol.45 (5), p.101713-101713, Article 101713

2021

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences
(20)
Science & Technology
(19)
Life Sciences & Biomedicine
(16)
Humans
(14)
Covid-19
(11)
Infectious Diseases
(11)
Santé Publique Et Épidémiologie
(8)
Sars-Cov-2
(8)
Adult
(7)
Human Health And Pathology
(7)
Severe Acute Respiratory Syndrome Coronavirus 2
(7)
Gastroenterology & Hepatology
(6)
Infections
(6)
Middle Aged
(6)
Prospective Studies
(6)
Female
(5)
Hepatitis C
(5)
Serology
(5)
Cancer
(4)
Coronaviruses
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The dynamic effect of direct‐acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C

Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers

Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort

Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort

Letter: tenofovir may be superior to entecavir for treatment‐naïve chronic hepatitis B patients—authors’ reply

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic

Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population

ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study

Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model

Publisher Correction: Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population

Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution

Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study

Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France

Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies

Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study

Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir

Time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir

Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response

Corrigendum to: Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study

Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study

Suchergebnisse filtern